Publications by authors named "L A Marzilli"

The higher order structure (HOS) of monoclonal antibodies (mAbs) is an important quality attribute with strong contribution to clinically relevant biological functions and drug safety. Due to the multi-faceted nature of HOS, the synergy of multiple complementary analytical approaches can substantially improve the understanding, accuracy, and resolution of HOS characterization. In this study, we applied one- and two-dimensional (1D and 2D) nuclear magnetic resonance (NMR) spectroscopy coupled with chemometric analysis, as well as circular dichroism (CD), differential scanning calorimetry (DSC), and fluorescence spectroscopy as orthogonal methods, to characterize the impact of methionine (Met) oxidation on the HOS of an IgG1 mAb.

View Article and Find Full Text PDF

The application of advanced methodologies such as next-generation sequencing (NGS) and mass spectrometry (MS) to the characterization of cell lines and recombinant proteins has enabled the highly sensitive detection of sequence variants (SVs). However, although these approaches can be leveraged to provide deep insight into product microheterogeneity caused by SVs, they are not used in a standardized manner across the industry. Currently, there is little clarity and consensus on the utilization, timing, and significance of SV findings.

View Article and Find Full Text PDF

Ligands that coordinate via dianionic phosphonate groups have not been widely utilized in radiopharmaceuticals. -(phosphonomethyl)iminodiacetic acid (, PMIDA) and (phosphonomethyl)glycine (, PMG) were investigated as new chelators for the Tc/Re-tricarbonyl "core" (-M(CO), M = Tc, Re) present in a major class of radiopharmaceuticals. fac-M(CO)(PMIDA) and fac-M(CO)(PMG) complexes were studied by HPLC and H/C/P NMR methods for M = Re ( and ) and by HPLC for M = Tc ( and ).

View Article and Find Full Text PDF
Article Synopsis
  • Amino acid sequence variation in protein therapeutics needs careful tracking during cell line and culture development to ensure product quality.
  • A collaborative team at Pfizer developed a reliable testing strategy over six years, utilizing next-generation sequencing (NGS) and amino acid analysis (AAA) to efficiently identify genetic mutations and misincorporations in mammalian cell clones.
  • By switching from mass spectrometry to NGS and AAA for routine monitoring, Pfizer improved efficiency and freed up resources for more detailed product quality assessments in the later stages of development.
View Article and Find Full Text PDF

NMR and X-ray diffraction studies were conducted on Pt(II)LCl complexes prepared with the new N-donor ligands N(SOR)Me dpa (R = Me, Tol; n = 2, 4). These ligands differ from N(H)dpa (di-2-picolylamine) in having the central N within a tertiary sulfonamide group instead of a secondary amine group and having Me groups at the 6,6'-positions ( n = 2) or 3,3',5,5'-positions ( n = 4) of the pyridyl rings. The N(SOR)3,3',5,5'-Medpa ligands are coordinated in a bidentate fashion in Pt( N(SOR)3,3',5,5'-Medpa)Cl complexes, forming a rare eight-membered chelate ring.

View Article and Find Full Text PDF